English Edition
English Articles
Native-English Drugnews analysis for global biotech, pharma, investor-relations, and capital-market readers.
The Next Phase of AI Drug Development: Making Molecules Survive as Drugs
AI drug development is moving from molecular generation to clinical survival. AnHorn Medicines shows how AI+PROTAC, experimental feedback, and human translation may form a Taiwan-born clinical-asset engine.
Where Does AI Drug Discovery Stand Now? A Pipeline-Based Reality Check
AI drug discovery has moved beyond the concept stage and into clinical validation. This article reviews Zasocitinib, GB-0895, Zovegalisib, and REC-4881 to examine how different AI strategies are being converted into real drug assets.
Obesity Becomes King: How GLP-1 Is Reshuffling Global Biotech Capital
A Drugnews English brief on Obesity Becomes King: How GLP-1 Is Reshuffling Global Biotech Capital, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.
RAS Targeting Opens a New Pancreatic-Cancer Window: How Senhwa's CX-5461 Positions for the Next Resistance-Management War
A Drugnews English brief on RAS Targeting Opens a New Pancreatic-Cancer Window: How Senhwa's CX-5461 Positions for the Next Resistance-Management War, focusing on company strategy, clinical evidence, company strategy, business development, and biotech capital-market implications.
Biotech IR Is Not Making Slides Prettier; It Is Turning Pipelines Into Trackable Capital-Market Stories
A Drugnews English brief on Biotech IR Is Not Making Slides Prettier; It Is Turning Pipelines Into Trackable Capital-Market Stories, focusing on capital markets, clinical evidence, company strategy, business development, and biotech capital-market implications.
The US$7 Billion Radiopharma Deal Rumor: Curium Wants Lantheus, but the Real Prize Is a Ticket to the Nuclear-Medicine Era
A Drugnews English brief on The US$7 Billion Radiopharma Deal Rumor: Curium Wants Lantheus, but the Real Prize Is a Ticket to the Nuclear-Medicine Era, focusing on radiopharma, clinical evidence, company strategy, business development, and biotech capital-market implications.
CAR-T Enters a New Era: From Blood Cancer to Autoimmune Disease
A Drugnews English brief on CAR-T Enters a New Era: From Blood Cancer to Autoimmune Disease, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.
Drugmakers Without AI Capability May No Longer Be Called Drugmakers
A Drugnews English brief on Drugmakers Without AI Capability May No Longer Be Called Drugmakers, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.
Old Targets Are Crowded, but They Can Still Make Money
A Drugnews English brief on Old Targets Are Crowded, but They Can Still Make Money, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.
Starting With Ruxolitinib Cream: Why Not Every JAK Molecule Can Become a Topical Drug
A Drugnews English brief on Starting With Ruxolitinib Cream: Why Not Every JAK Molecule Can Become a Topical Drug, focusing on company strategy, clinical evidence, company strategy, business development, and biotech capital-market implications.
Retatrutide Moves Toward Surgery-Level Weight Loss: Lilly's Triple-Agonist Pushes Obesity Treatment Into a New Arena
A Drugnews English brief on Retatrutide Moves Toward Surgery-Level Weight Loss: Lilly's Triple-Agonist Pushes Obesity Treatment Into a New Arena, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.
A Genetic Disease With No New Treatment for 40 Years Finally Enters a New Drug Era
A Drugnews English brief on A Genetic Disease With No New Treatment for 40 Years Finally Enters a New Drug Era, focusing on immunology, clinical evidence, company strategy, business development, and biotech capital-market implications.
Biogen's High-Risk Bet: Can Tau Find a Way Out of the Alzheimer's R&D Graveyard?
A Drugnews English brief on Biogen's High-Risk Bet: Can Tau Find a Way Out of the Alzheimer's R&D Graveyard?, focusing on cns, clinical evidence, company strategy, business development, and biotech capital-market implications.
Pluvicto Is Selling Fast: What Radioligand Therapy Growth Really Means
A Drugnews English brief on Pluvicto Is Selling Fast: What Radioligand Therapy Growth Really Means, focusing on radiopharma, clinical evidence, company strategy, business development, and biotech capital-market implications.
The Tavneos Crisis: Death Reports, Data-Integrity Questions, and an Amgen Rare-Disease Star at the Edge of Withdrawal
A Drugnews English brief on The Tavneos Crisis: Death Reports, Data-Integrity Questions, and an Amgen Rare-Disease Star at the Edge of Withdrawal, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications.
The Best Partner for a Drug King? When Combination Therapy Doubles Efficacy
A Drugnews English brief on The Best Partner for a Drug King? When Combination Therapy Doubles Efficacy, focusing on company strategy, clinical evidence, company strategy, business development, and biotech capital-market implications.
Weight-Loss Drugs Are No Longer Only About Body Weight: Where Next-Generation Therapies Are Aiming
A Drugnews English brief on Weight-Loss Drugs Are No Longer Only About Body Weight: Where Next-Generation Therapies Are Aiming, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.
Biotech Investing Needs a Judgment System, Not More News
A Drugnews English brief on Biotech Investing Needs a Judgment System, Not More News, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.
The First Step in Valuing Taiwanese Biotech: Stop Forcing Every Company Into the Same P/E Ratio
A Drugnews English brief on The First Step in Valuing Taiwanese Biotech: Stop Forcing Every Company Into the Same P/E Ratio, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.
Sun Pharma, Teva, and the Transformation Anxiety of Global Generic Drugmakers
A Drugnews English brief on Sun Pharma, Teva, and the Transformation Anxiety of Global Generic Drugmakers, focusing on big pharma, clinical evidence, company strategy, business development, and biotech capital-market implications.
A New Weight-Loss Drug Side Effect Accidentally Opens a New Therapeutic Track
A Drugnews English brief on A New Weight-Loss Drug Side Effect Accidentally Opens a New Therapeutic Track, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.
Asthma Drugs Are Shifting Gears: From Triple Inhalers to Upstream Immune Targets
A Drugnews English brief on Asthma Drugs Are Shifting Gears: From Triple Inhalers to Upstream Immune Targets, focusing on immunology, clinical evidence, company strategy, business development, and biotech capital-market implications.
Why OX2R Is Heating Up: From Narcolepsy to the Next CNS Drug Opportunity
A Drugnews English brief on Why OX2R Is Heating Up: From Narcolepsy to the Next CNS Drug Opportunity, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.
The Global Biotech Wave: Understanding the Main Phase and Scientific Pricing of the Five-Trillion Weight-Loss Market
A Drugnews English brief on The Global Biotech Wave: Understanding the Main Phase and Scientific Pricing of the Five-Trillion Weight-Loss Market, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.
How Mid-Sized Biotechs Are Turning Blockbuster Drugs From Dreams Into Cash Flow
A Drugnews English brief on How Mid-Sized Biotechs Are Turning Blockbuster Drugs From Dreams Into Cash Flow, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.
How AI Semiconductors Have Hidden the Biotech Opportunity in Plain Sight
A Drugnews English brief on How AI Semiconductors Have Hidden the Biotech Opportunity in Plain Sight, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.
A Record AI Drug-Discovery Financing: Why a Google-Backed Company Raised US$2.1 Billion
A Drugnews English brief on A Record AI Drug-Discovery Financing: Why a Google-Backed Company Raised US$2.1 Billion, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.
HIV Drugs Are Still Highly Profitable: What Gilead's Earnings Reveal
A Drugnews English brief on HIV Drugs Are Still Highly Profitable: What Gilead's Earnings Reveal, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.
Where Pfizer Misjudged the Vepdegestrant Strategy
A Drugnews English brief on Where Pfizer Misjudged the Vepdegestrant Strategy, focusing on targeted therapy, clinical evidence, company strategy, business development, and biotech capital-market implications.
Johnson & Johnson Cuts Two Autologous Lymphoma CAR-T Programs
A Drugnews English brief on Johnson & Johnson Cuts Two Autologous Lymphoma CAR-T Programs, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.
Daiichi Sankyo's Most Expensive Lesson: How an ADC Capacity Bet Can Backfire After a Blockbuster
A Drugnews English brief on Daiichi Sankyo's Most Expensive Lesson: How an ADC Capacity Bet Can Backfire After a Blockbuster, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.
The FDA Commissioner's Exit: Why the World's Most Important Drug Referee Is Becoming Less Predictable
A Drugnews English brief on The FDA Commissioner's Exit: Why the World's Most Important Drug Referee Is Becoming Less Predictable, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications.
A Complete Map of the New Antidepressant Drug Pipeline
A Drugnews English brief on A Complete Map of the New Antidepressant Drug Pipeline, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.
How PharmaEssentia's Besremi Opens a Larger Valuation Imagination
A Drugnews English brief on How PharmaEssentia's Besremi Opens a Larger Valuation Imagination, focusing on targeted therapy, clinical evidence, company strategy, business development, and biotech capital-market implications.
Could Neuroinflammation Bring CNS Drug Development Back?
A Drugnews English brief on Could Neuroinflammation Bring CNS Drug Development Back?, focusing on cns, clinical evidence, company strategy, business development, and biotech capital-market implications.
The Autoimmune Twins That Could Save Johnson & Johnson
A Drugnews English brief on The Autoimmune Twins That Could Save Johnson & Johnson, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.
Could DAC Become the Next Breakout Format in Targeted Therapy?
A Drugnews English brief on Could DAC Become the Next Breakout Format in Targeted Therapy?, focusing on targeted therapy, clinical evidence, company strategy, business development, and biotech capital-market implications.
Trump Delays the Policy Signal: Did Weight-Loss Drugs Cut Prices for Nothing?
A Drugnews English brief on Trump Delays the Policy Signal: Did Weight-Loss Drugs Cut Prices for Nothing?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.
Clinical-Trial Fraud and an FDA Withdrawal Storm
A Drugnews English brief on Clinical-Trial Fraud and an FDA Withdrawal Storm, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications.
Weight-Loss Drugs Are Still Too Strong: Lilly's Mounjaro Keeps Printing Money
A Drugnews English brief on Weight-Loss Drugs Are Still Too Strong: Lilly's Mounjaro Keeps Printing Money, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.
The Shadow Behind the Next Century-Defining Drug
A Drugnews English brief on The Shadow Behind the Next Century-Defining Drug, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.
Free Taipei Workshop: Using an NPV Framework to Identify Biotech Re-Rating Points
A Drugnews English brief on Free Taipei Workshop: Using an NPV Framework to Identify Biotech Re-Rating Points, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.
What Makes a Pipeline Attractive to Big Pharma?
A Drugnews English brief on What Makes a Pipeline Attractive to Big Pharma?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.
The Hair-Growth Drug That Jumped 47%: Why It Could Rewrite Three Decades of Hair-Loss Treatment
A Drugnews English brief on The Hair-Growth Drug That Jumped 47%: Why It Could Rewrite Three Decades of Hair-Loss Treatment, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.
In Vivo CAR-T: Bubble or the Most Expensive Ticket to Next-Generation Cell Therapy?
A Drugnews English brief on In Vivo CAR-T: Bubble or the Most Expensive Ticket to Next-Generation Cell Therapy?, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.
The Ambition of an Indian Pharma Giant: Acquiring a US Drugmaker
A Drugnews English brief on The Ambition of an Indian Pharma Giant: Acquiring a US Drugmaker, focusing on big pharma, clinical evidence, company strategy, business development, and biotech capital-market implications.
Is the 20-Year Amyloid Hypothesis in Alzheimer's Disease Starting to Collapse?
A Drugnews English brief on Is the 20-Year Amyloid Hypothesis in Alzheimer's Disease Starting to Collapse?, focusing on cns, clinical evidence, company strategy, business development, and biotech capital-market implications.
Amazon Enters AI Drug Discovery and Challenges Nvidia's Pharma Ambition
A Drugnews English brief on Amazon Enters AI Drug Discovery and Challenges Nvidia's Pharma Ambition, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.
A Clear Read on Lilly's Current M&A Logic
A Drugnews English brief on A Clear Read on Lilly's Current M&A Logic, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.
When a Gray-Market Industry Gets a Seat at the Table
A Drugnews English brief on When a Gray-Market Industry Gets a Seat at the Table, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.
Goodbye Autologous CAR-T: Why Taiwan's Cell-Therapy Bubble Also Needs to Break
A Drugnews English brief on Goodbye Autologous CAR-T: Why Taiwan's Cell-Therapy Bubble Also Needs to Break, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.
The Healthcare-Giant Spin-Off Wave
A Drugnews English brief on The Healthcare-Giant Spin-Off Wave, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.
Why Platform Biotechs Can Generate Five Times More Licensing Revenue
A Drugnews English brief on Why Platform Biotechs Can Generate Five Times More Licensing Revenue, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.
Investors Should Pay Attention: Drug Delivery Is a Blue Ocean
A Drugnews English brief on Investors Should Pay Attention: Drug Delivery Is a Blue Ocean, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.
Do COPD Patients Finally Have Another New Drug Option?
A Drugnews English brief on Do COPD Patients Finally Have Another New Drug Option?, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.
The Three AI Giants Battling Inside Medicine
A Drugnews English brief on The Three AI Giants Battling Inside Medicine, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.
Did Lilly's Oral Drug Ignite the Market?
A Drugnews English brief on Did Lilly's Oral Drug Ignite the Market?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.
A Historic Moment: The Next Century-Defining Drug Has Arrived
A Drugnews English brief on A Historic Moment: The Next Century-Defining Drug Has Arrived, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.
Neuralink and the Next Trillion-Dollar Race: Ten Brain-Computer Interface Companies to Know
A Drugnews English brief on Neuralink and the Next Trillion-Dollar Race: Ten Brain-Computer Interface Companies to Know, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.
Could This Taiwanese Biotech Capture the Entire AI Infrastructure Dividend?
A Drugnews English brief on Could This Taiwanese Biotech Capture the Entire AI Infrastructure Dividend?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.
The Valley of Death in Innovative Drug Development
A Drugnews English brief on The Valley of Death in Innovative Drug Development, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.
The 2026 Q2 Drug Catalysts Biotech Readers Need to Know
A Drugnews English brief on The 2026 Q2 Drug Catalysts Biotech Readers Need to Know, focusing on immunology, clinical evidence, company strategy, business development, and biotech capital-market implications.
The Fall of Two Star Biotechs
A Drugnews English brief on The Fall of Two Star Biotechs, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.
Investors Should Pay Attention to the Autoimmune Mega-Drug Race
A Drugnews English brief on Investors Should Pay Attention to the Autoimmune Mega-Drug Race, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.
The King of Weight-Loss Drugs: Did US$7.8 Billion Buy the Next Era of Metabolic Medicine?
A Drugnews English brief on The King of Weight-Loss Drugs: Did US$7.8 Billion Buy the Next Era of Metabolic Medicine?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.
Idiopathic Pulmonary Fibrosis Is Entering an Acceleration Phase
A Drugnews English brief on Idiopathic Pulmonary Fibrosis Is Entering an Acceleration Phase, focusing on immunology, clinical evidence, company strategy, business development, and biotech capital-market implications.
Why Did the Market Like This Company More After a Clinical Failure?
A Drugnews English brief on Why Did the Market Like This Company More After a Clinical Failure?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.
When Should a Company Decisively Abandon a Clinical Trial?
A Drugnews English brief on When Should a Company Decisively Abandon a Clinical Trial?, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.
A New Drug Finally Arrives for This Group of Rare-Disease Patients
A Drugnews English brief on A New Drug Finally Arrives for This Group of Rare-Disease Patients, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.
The Abivax Story: How a European Biotech Became a 14-Fold Market Myth
A Drugnews English brief on The Abivax Story: How a European Biotech Became a 14-Fold Market Myth, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.
While the US CDC Was Still Looking for a Director
A Drugnews English brief on While the US CDC Was Still Looking for a Director, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications.
The Cut-Rate Weight-Loss Injection Has Arrived: What a NT$420 Monthly Price Really Means
A Drugnews English brief on The Cut-Rate Weight-Loss Injection Has Arrived: What a NT$420 Monthly Price Really Means, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.
How Far Are We From a Real Anti-Aging Drug?
A Drugnews English brief on How Far Are We From a Real Anti-Aging Drug?, focusing on clinical development, clinical evidence, company strategy, business development, and biotech capital-market implications.
Did Weight-Loss Injections Backfire and Trigger Pancreatitis Risk?
A Drugnews English brief on Did Weight-Loss Injections Backfire and Trigger Pancreatitis Risk?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.
After GLP-1 and Mounjaro, What Is Happening in Weight-Loss Drug R&D?
A Drugnews English brief on After GLP-1 and Mounjaro, What Is Happening in Weight-Loss Drug R&D?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.
Can Merck Build Another Oncology Empire?
A Drugnews English brief on Can Merck Build Another Oncology Empire?, focusing on big pharma, clinical evidence, company strategy, business development, and biotech capital-market implications.
Innovent's Globalization Train: Did Taiwan's Forward Therapeutics Get On Board?
A Drugnews English brief on Innovent's Globalization Train: Did Taiwan's Forward Therapeutics Get On Board?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.